Loading...
NPI 1013055110 · St Johnsbury, VT · Substance Use Disorder Rehabilitation Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Baart Behavioral Health Services, Inc. is a substance use disorder rehabilitation clinic/center provider located in St Johnsbury, Vermont. This profile covers 4 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Baart Behavioral Health Services, Inc. |
| Address | 1097 Hospital Dr |
| City | St Johnsbury |
| State | VT |
| ZIP | 05819 |
| Taxonomy | Substance Use Disorder Rehabilitation Clinic/Center |
| NPI Enumerated | February 1, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $3.5M |
| Medicare | $559K |
Tenure and service taxonomy: BAART BEHAVIORAL HEALTH SERVICES, INC. is enumerated under NPI as of 2007-02-01 (~19 years ago) and is categorized as a Substance Use Disorder Rehabilitation Clinic/Center, consistent with sustained operation as an opioid treatment program (OTP) level provider over nearly two decades. The long tenure supports continuity in delivering medication-assisted treatment (MAT) services in the ST JOHNSBURY VT market.
Payer mix and scale: Lifetime Medicaid revenue ($3.5M) substantially exceeds lifetime Medicare revenue ($559K), indicating this location is effectively Medicaid-dominant in scale. Analysts should treat Medicaid as the primary commercial payer relationship for evaluating patient volume and local market impact.
Medicare revenue concentration and service line: Medicare revenue is overwhelmingly driven by OTP weekly bundles — the top 3 Medicare codes account for 99.7% of the provider's Medicare revenue, and G2067 alone generates $524.2K (93.8% of Medicare revenue). G2067 (medication assisted treatment, methadone; weekly bundle) being the dominant Medicare code indicates the provider’s Medicare-facing activity is principally OTP methadone dispensing and associated counseling/toxicology services.
Medicare competitive standing: For its Medicare top code G2067 the provider ranks #62 of 830 nationally (93th percentile) and is labeled as typical, unremarkable volume, meaning this location participates at a modest but non-negligible level among national OTPs billing Medicare. Secondary Medicare codes (G2078, G2074, G2077) show much smaller contributions and lower percentile ranks, reinforcing that Medicare activity is concentrated in the single weekly bundle code.
Medicaid revenue concentration and service line: Medicaid revenue is almost entirely concentrated in methadone administration/service — H0020 accounts for $3.5M and 99.5% of the provider's Medicaid revenue. This pattern points to a primary operational focus on methadone treatment and related services for Medicaid beneficiaries rather than broader outpatient medical care.
Medicaid competitive standing and in-state context: H0020 activity ranks #5 of 9 in-state (50th percentile; typical, unremarkable volume), so the provider is a mid-ranked, established in-state supplier of methadone services rather than a dominant statewide operator. Other Medicaid codes such as G2067 and E/M codes (99214, 99213) contribute only trace revenue in-state, further indicating Medicaid business is concentrated in methadone dispensing.
Unusual claim-payment pattern for buprenorphine products: The provider reports large claim counts for J0574 (12.8K claims) and other buprenorphine NDC-level codes (J0572, J0575) but these rows show $0 avg paid/claim and $0 revenue despite high claim volumes; J0574 ranks #2 of 7 in-state (83th percentile). This discrepancy suggests an alternative payment or reporting pathway for buprenorphine at this site (e.g., separate pharmacy reimbursement or non-fee-for-service flow) and should be investigated when reconciling service volume with paid dollars.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 2,300 | $230 | $524.2K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | 470 | $40 | $18.1K |
| G2074 | Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services… | 80 | $190 | $14.8K |
| G2077 | Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and… | 20 | $110 | $1.9K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 17,110 | $210 | $3.5M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 120 | $70 | $8.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 70 | $110 | $7.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 50 | $40 | $1.9K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 1,470 | $0 | $0 |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 12,770 | $0 | $0 |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 1,040 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Vermont providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Vermont median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 5 | 10 | 17,110 | $40 | $13.6M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 4 | 10 | 120 | $190 | $4.1M |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 5 | 10 | 1,360 | $50 | $551.1K |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 2 | 10 | 6,550 | $30 | $483.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 271 | 320 | 680 | $30 | $146.1K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 4 | 10 | 1,470 | $10 | $107.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 276 | 320 | 760 | $20 | $88.2K |
Other providers in the same ZIP code as Baart Behavioral Health Services, Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.